FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126944781> ?p ?o ?g. }

• W3126944781 abstract "Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths. The rapid deployment of antibody-based countermeasures has provided hope for curtailing disease and ending the pandemic 1 . However, the emergence of rapidly-spreading SARS-CoV-2 variants in the United Kingdom (B.1.1.7), South Africa (B.1.351), and elsewhere with mutations in the spike protein has raised concern for escape from neutralizing antibody responses and loss of vaccine efficacy based on preliminary data with pseudoviruses 2-4 . Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera, and human sera from recipients of the Pfizer-BioNTech (BNT162b2) mRNA vaccine, we report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.1.7 isolate, a chimeric Washington strain with a South African spike gene (Wash SA-B.1.351), and isogenic recombinant variants with designed mutations or deletions at positions 69-70, 417, 484, 501, and/or 614 of the spike protein. Several highly neutralizing mAbs engaging the receptor binding domain (RBD) or N-terminal domain (NTD) lost inhibitory activity against Wash SA-B.1.351 or recombinant variants with an E484K spike mutation. Most convalescent sera and virtually all mRNA vaccine-induced immune sera tested showed markedly diminished neutralizing activity against the Wash SA-B.1.351 strain or recombinant viruses containing mutations at position 484 and 501. We also noted that cell line selection used for growth of virus stocks or neutralization assays can impact the potency of antibodies against different SARS-CoV-2 variants, which has implications for assay standardization and congruence of results across laboratories. As several antibodies binding specific regions of the RBD and NTD show loss-of-neutralization potency in vitro against emerging variants, updated mAb cocktails, targeting of highly conserved regions, enhancement of mAb potency, or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo ." @default.
• W3126944781 created "2021-02-15" @default.
• W3126944781 creator A5002409017 @default.
• W3126944781 creator A5006817344 @default.
• W3126944781 creator A5009632243 @default.
• W3126944781 creator A5013365298 @default.
• W3126944781 creator A5014815375 @default.
• W3126944781 creator A5023363049 @default.
• W3126944781 creator A5025961798 @default.
• W3126944781 creator A5026274834 @default.
• W3126944781 creator A5032281507 @default.
• W3126944781 creator A5035720803 @default.
• W3126944781 creator A5036038306 @default.
• W3126944781 creator A5036962368 @default.
• W3126944781 creator A5040891206 @default.
• W3126944781 creator A5043016585 @default.
• W3126944781 creator A5047654289 @default.
• W3126944781 creator A5048559404 @default.
• W3126944781 creator A5056393456 @default.
• W3126944781 creator A5056972396 @default.
• W3126944781 creator A5057281614 @default.
• W3126944781 creator A5057764651 @default.
• W3126944781 creator A5059907217 @default.
• W3126944781 creator A5061263271 @default.
• W3126944781 creator A5063694206 @default.
• W3126944781 creator A5067271594 @default.
• W3126944781 creator A5070010822 @default.
• W3126944781 creator A5070153307 @default.
• W3126944781 creator A5081470274 @default.
• W3126944781 creator A5084174098 @default.
• W3126944781 creator A5086125514 @default.
• W3126944781 creator A5087556999 @default.
• W3126944781 creator A5089168453 @default.
• W3126944781 date "2021-02-10" @default.
• W3126944781 modified "2023-10-18" @default.
• W3126944781 title "SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies" @default.
• W3126944781 cites W2103441770 @default.
• W3126944781 cites W2106578986 @default.
• W3126944781 cites W2734356283 @default.
• W3126944781 cites W2889664156 @default.
• W3126944781 cites W2951912016 @default.
• W3126944781 cites W3015751519 @default.
• W3126944781 cites W3025744748 @default.
• W3126944781 cites W3030146162 @default.
• W3126944781 cites W3034548712 @default.
• W3126944781 cites W3037426855 @default.
• W3126944781 cites W3040017923 @default.
• W3126944781 cites W3040899749 @default.
• W3126944781 cites W3042323010 @default.
• W3126944781 cites W3049654234 @default.
• W3126944781 cites W3081204841 @default.
• W3126944781 cites W3086125063 @default.
• W3126944781 cites W3089112814 @default.
• W3126944781 cites W3091791643 @default.
• W3126944781 cites W3093768302 @default.
• W3126944781 cites W3095217725 @default.
• W3126944781 cites W3096064145 @default.
• W3126944781 cites W3099530525 @default.
• W3126944781 cites W3104722250 @default.
• W3126944781 cites W3111255098 @default.
• W3126944781 cites W3113134471 @default.
• W3126944781 cites W3119858919 @default.
• W3126944781 cites W3120079728 @default.
• W3126944781 cites W3121008609 @default.
• W3126944781 cites W3121833403 @default.
• W3126944781 cites W3121995178 @default.
• W3126944781 cites W3122148095 @default.
• W3126944781 cites W3123175540 @default.
• W3126944781 cites W3123633513 @default.
• W3126944781 cites W3126729284 @default.
• W3126944781 cites W3127401064 @default.
• W3126944781 doi "https://doi.org/10.21203/rs.3.rs-228079/v1" @default.
• W3126944781 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7885928" @default.
• W3126944781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33594356" @default.
• W3126944781 hasPublicationYear "2021" @default.
• W3126944781 type Work @default.
• W3126944781 sameAs 3126944781 @default.
• W3126944781 citedByCount "62" @default.
• W3126944781 countsByYear W31269447812020 @default.
• W3126944781 countsByYear W31269447812021 @default.
• W3126944781 countsByYear W31269447812022 @default.
• W3126944781 countsByYear W31269447812023 @default.
• W3126944781 crossrefType "posted-content" @default.
• W3126944781 hasAuthorship W3126944781A5002409017 @default.
• W3126944781 hasAuthorship W3126944781A5006817344 @default.
• W3126944781 hasAuthorship W3126944781A5009632243 @default.
• W3126944781 hasAuthorship W3126944781A5013365298 @default.
• W3126944781 hasAuthorship W3126944781A5014815375 @default.
• W3126944781 hasAuthorship W3126944781A5023363049 @default.
• W3126944781 hasAuthorship W3126944781A5025961798 @default.
• W3126944781 hasAuthorship W3126944781A5026274834 @default.
• W3126944781 hasAuthorship W3126944781A5032281507 @default.
• W3126944781 hasAuthorship W3126944781A5035720803 @default.
• W3126944781 hasAuthorship W3126944781A5036038306 @default.
• W3126944781 hasAuthorship W3126944781A5036962368 @default.
• W3126944781 hasAuthorship W3126944781A5040891206 @default.
• W3126944781 hasAuthorship W3126944781A5043016585 @default.
• W3126944781 hasAuthorship W3126944781A5047654289 @default.
• W3126944781 hasAuthorship W3126944781A5048559404 @default.
• W3126944781 hasAuthorship W3126944781A5056393456 @default.

• next